Replies to post #219766 on Avid Bioservices Inc (CDMO)

[PastPresentFuture]

http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=907312

[InternetForumUser]

It is from the April 20, 2015 Peregrine PR.

http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=907312

[cjgaddy]

N40K, that quote by Nilogen Oncosystems' (Moffitt startup) Dr. Sigrid M. Volko about clinical translational data from the UTSW/Yopp Liver IST as applied to Lung Cancer came from Peregrine's 4-20-15 AACR'15 (Abstract #274) press release:
See: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112903784

"Our translational findings of a cytokine profile that reflects an immune response following either bavituximab single-agent or combination treatment are encouraging. Furthermore, these preliminary translational data show that tumors with negative PD-L1 expression and low levels of PD-1 expression on CD8+ tumor infiltrating T cells showed immune response to bavituximab treatment ex vivo," said Sigrid M. Volko, Ph.D., CLP the lead investigator on the study and President & CEO of Nilogen Oncosystems [=Moffit Startup: http://otmc.moffitt.org/startups.aspx ]. "It is an exciting time for the field of immunotherapy and the data we have been generating support that bavituximab has the potential to activate a tumor specific immune response in patients with PD-L1 negative tumors that generally do not respond as well to PD-1 or PD-L1 inhibitors."